Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
Avacta Group PLC (AVCT.L) New appointments to Scientific Advisory Board
Avacta Group PLC (AVCT.L) Diagnostics achieves ISO 13485 Certification
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics
Avacta Group PLC (AVCT.L) AffiDX Lateral Flow Test Detects Delta Variant
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown
Midatech Pharma PLC (MTPH.L) Breakthrough data using Q-Sphera technology
Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes
Avacta Group PLC (AVCT.L) Registration of AffiDX Lateral Flow Test in EU
Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU
Futura Medical PLC (FUM.L) Notice of AGM and Annual Report
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused
Avacta Group PLC (AVCT.L) Response to speculation
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes speculation regarding the ongoing CE mark submission for
Avacta Group PLC (AVCT.L) Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and
Avacta Group PLC (AVCT.L) AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
Submission of Declaration of Conformity for CE mark for Avacta’s rapid antigen test
Avacta Group PLC (AVCT.L) Final Results
Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
